An expert on urothelial carcinoma reviews the case of a 76-year-old patient with advanced, resectable urothelial carcinoma.
Case 2: A 76-Year Old Man with Locally Advanced, Resectable Urothelial Carcinoma
Initial Clinical Presentation:
Initial Clinical Workup:
Treatment and Disease Progression:
This is a synopsis of a Case-Based Peer Perspectives series featuring Scott T. Tagawa, MD, MS, FACP, FASCO, of Weill Cornell Medicine.
Scott T. Tagawa, MD, MS, FACP, FASCO presented a case of a 76-year-old male with metastatic urothelial carcinoma involving the bladder and multiple liver metastases. His kidney function was impaired with an estimated glomerular filtration rate (eGFR) of 45 mL/min, making him ineligible for cisplatin chemotherapy. Molecular testing was negative for FGFR alterations.
With metastatic disease and good performance status but cisplatin-ineligibility, combination immunotherapy was recommended over single agent chemotherapy. Dr. Tagawa noted that the combination of enfortumab vedotin (an antibody-drug conjugate targeting Nectin-4) plus pembrolizumab is given on a 3-week cycle, with enfortumab vedotin dosed on days 1 and 8 and pembrolizumab at 200 mg flat dose every 3 weeks.
This patient developed a maculopapular rash after starting therapy that improved with topical steroids. He achieved a partial response after 6 cycles but then had persistent grade 2 neuropathy requiring enfortumab vedotin discontinuation. Pembrolizumab was continued as maintenance, but he eventually had disease progression.
Next treatment was sacituzumab govitecan on day 1 and day 8 of a 21-day cycle, typically at 10 mg/kg. Dr. Tagawa again reviewed that key adverse events with this Trop-2 antibody-drug conjugate are neutropenia and diarrhea, requiring monitoring and potential dose modifications.
In conclusion, Dr. Tagawa walked through treatment decision-making in a cisplatin-ineligible patient with advanced urothelial carcinoma. The case highlighted evolving use of immunotherapy combinations and newer antibody-drug conjugates for patients progressing after first-line immunotherapy. Molecular profiling for biomarker-driven therapy eligibility should be incorporated at diagnosis and upon progression.
*Video synopsis is AI-generated and reviewed by Urology Times editorial staff.
Speaking of Urology Podcast: Dr. Ritch and Dr. Katz discuss new bladder cancer management app
December 7th 2021“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.